Scopolamine

Anticholinergic — ALIMENTARY TRACT AND METABOLISM

Key facts

Scopolamine is an ofp drug in the Anticholinergic class catalogued in DrugCentral. It was first approved by the FDA in 1979. Its mechanism of action is classified as Cholinergic Antagonists. DrugCentral lists 11 molecular targets, including Chrm1|Chrm3|Chrm4|Chrm5|Chrm2, CHRM3 and Muscarinic receptor M1. Recorded indications include Allergic rhinitis, Common cold, Cough and Cycloplegia.

• Approval status: ofp (first approved 1979 by the FDA).
• Drug class: Anticholinergic.
• Mechanism of action: Cholinergic Antagonists.
• Molecular targets: Chrm1|Chrm3|Chrm4|Chrm5|Chrm2, CHRM3, Muscarinic receptor M1 and CHRM4 (11 listed in DrugCentral).
• Indications: Allergic rhinitis, Common cold, Cough, Cycloplegia and Dilated pupil and others.
• ATC code: A04AD01 (Other antiemetics).
• Molecular formula: C17H21NO4; molecular weight 303.36 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (18)

• Allergic rhinitis
• Common cold
• Cough
• Cycloplegia
• Dilated pupil
• Iridocyclitis
• Irritable bowel syndrome
• Motion sickness
• Nasal congestion
• Nasal discharge
• Peptic ulcer
• Perioperative Mydriasis
• Posterior synechiae
• Prevention of motion sickness
• Prevention of Post-Operative Nausea and Vomiting
• Prevention of Posterior Synechiae
• Uveitis
• Vasomotor rhinitis

Off-label uses (4)

• Excessive salivation
• General anesthesia
• Rhinitis
• Seasonal allergic rhinitis

Contraindications (78)

• Achalasia of esophagus
• Acidosis
• Acute hepatitis
• Acute pancreatitis
• Alcohol intoxication
• Alcoholism
• Anemia
• Angle-closure glaucoma
• Arterial aneurysm
• Arterial thrombosis
• Arteriosclerotic vascular disease
• Atony of colon
• Autonomic dysreflexia
• Benign prostatic hyperplasia
• Bladder outflow obstruction
• Bleeding
• Bradycardia
• Brain damage
• Breastfeeding (mother)
• Chronic heart failure
• Chronic idiopathic constipation
• Chronic lung disease
• Chronic obstructive lung disease
• Complete trisomy 21 syndrome
• Conduction disorder of the heart
• Coronary arteriosclerosis
• Depressive disorder
• Diabetes mellitus
• Disease of liver
• Disorder of autonomic nervous system
• + 48 more

Mechanism & targets

• Mechanism of action (MoA): Cholinergic Antagonists
• Established pharmacologic class: Anticholinergic

Molecular targets (11)

Target	Gene	Action	Activity
Muscarinic acetylcholine receptor	Chrm1|Chrm3|Chrm4|Chrm5|Chrm2	unknown	Ki 10.10
Muscarinic acetylcholine receptor M3	CHRM3	unknown	Ki 9.40
Muscarinic receptor M1	—	unknown	Ki 9.39
Muscarinic acetylcholine receptor M4	CHRM4	unknown	Ki 9.37
Muscarinic acetylcholine receptor M1	Chrm1	unknown	Ki 9.28
Muscarinic acetylcholine receptor M3	Chrm3	unknown	Kd 9.19
Muscarinic acetylcholine receptor DM1	mAChR-A	unknown	Ki 9.15
Muscarinic acetylcholine receptor M1	CHRM1	antagonist	Ki 9.00
Muscarinic acetylcholine receptor M2	CHRM2	unknown	Ki 8.86
Muscarinic acetylcholine receptor M2	Chrm2	unknown	Kd 8.52
Muscarinic acetylcholine receptor M5	CHRM5	unknown	Ki 7.75

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1979-12-31	FDA	—	NOVARTIS

ATC classification

ATC code	Therapeutic hierarchy
A04AD01	ALIMENTARY TRACT AND METABOLISM › ANTIEMETICS AND ANTINAUSEANTS › ANTIEMETICS AND ANTINAUSEANTS › Other antiemetics
A04AD51	ALIMENTARY TRACT AND METABOLISM › ANTIEMETICS AND ANTINAUSEANTS › ANTIEMETICS AND ANTINAUSEANTS › Other antiemetics
N05CM05	NERVOUS SYSTEM › PSYCHOLEPTICS › HYPNOTICS AND SEDATIVES › Other hypnotics and sedatives
S01FA02	SENSORY ORGANS › OPHTHALMOLOGICALS › MYDRIATICS AND CYCLOPLEGICS › Anticholinergics

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Swollen tongue	210.3
Swelling face	192.4
Dysphonia	180.9
Angioedema	175.3
Drug ineffective for unapproved indication	162.5
Mydriasis	154.4
Anticholinergic syndrome	136.3
Neutrophil count increased	123.1
Antipsychotic drug level increased	95.5
Differential white blood cell count abnormal	95.1
Neuroleptic malignant syndrome	76.7
Product adhesion issue	74.7

Chemical structure

• Molecular formula: C₁₇H₂₁NO₄
• Molecular weight: 303.36 g/mol
• CAS number: —
• InChIKey: STECJAGHUSJQJN-VJQRDGCPSA-N
• PubChem CID: 3000322

CN1[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Scopolamine used for?

DrugCentral lists the following indications for Scopolamine: Allergic rhinitis, Common cold, Cough, Cycloplegia, Dilated pupil, Iridocyclitis, Irritable bowel syndrome and Motion sickness and others.

How does Scopolamine work?

Scopolamine is classified as Cholinergic Antagonists; its molecular targets in DrugCentral include Chrm1|Chrm3|Chrm4|Chrm5|Chrm2, CHRM3, Muscarinic receptor M1 and CHRM4.

When was Scopolamine first approved?

Scopolamine was first approved by the FDA in 1979.

What drug class does Scopolamine belong to?

Scopolamine is in the Anticholinergic class.

What is the chemical formula of Scopolamine?

Scopolamine has the molecular formula C17H21NO4 and a molecular weight of 303.36 g/mol.

Sources

• DrugCentral drug card 2424 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2251240 — compound record and bioactivity
• PubChem CID 3000322 — chemical identifiers
• DrugBank DB00747 — drug record
• FDA UNII DL48G20X8X — substance identity
• DailyMed: FDA labels for Scopolamine — current prescribing information (label search)
• UniProt P20309 (CHRM3) — target protein
• UniProt P08173 (CHRM4) — target protein
• UniProt P11229 (CHRM1) — target protein
• UniProt P08172 (CHRM2) — target protein
• UniProt P08912 (CHRM5) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.